Bo Nordenskjold
Linkoeping, E, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 92 publications
Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.
Journal: Journal of the National Cancer Institute
Published: October 13, 2025
Dose-dense anthracycline- and taxane-based chemotherapy remains the preferred treatment for selected patients with high-risk early breast cancer.
Journal: The Lancet regional health. Europe
Published: December 22, 2024
Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 15, 2024
Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial.
Journal: International journal of cancer
Published: October 25, 2024
Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.
Journal: Journal of the National Cancer Institute
Published: May 02, 2024
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer.
Journal: NPJ breast cancer
Published: April 17, 2024
Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up.
Journal: Acta oncologica (Stockholm, Sweden)
Published: April 05, 2024
Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit.
Journal: Acta oncologica (Stockholm, Sweden)
Published: September 28, 2023
Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial.
Journal: Breast cancer research : BCR
Published: June 28, 2023
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy.
Journal: Breast (Edinburgh, Scotland)
Published: May 21, 2023
Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 21, 2022
Last Updated: 09/26/2026